Author: 16by9

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a further major (global top-10) pharmaceutical client. Click here to read in full...

Physiomics plc is pleased to announce that it has been awarded a contract by a new major pharmaceutical client.  The project, which is expected to be completed during the Company's current financial year involves the use of Physiomics' Virtual Tumour technology in a pre-clinical setting and its value is approximately £35k. Click here to read in full...

The Company held its Annual General Meeting at its offices in Oxford on 13th December 2017 Click here to read more...

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share: Click here to read more....

Physiomics plc announces today that following the receipt of notice of exercise of employee options, 1,768,815 Ordinary Shares of 0.4p each in the Company (the “Options Shares”) have now been issued to the following employees at the following exercise prices: Please click here to read more....

Following the movement in the Physiomics share price today the Company would like to draw investors’ attention to its RNS of the 28th of November in which the Company announced the signing of a Master Services Agreement (“Agreement”) with Merck KGaA whose minimum value in the first twelve months of the contract is €500,000 (equivalent to around 60% of our net operating expenses for the...

Physiomics plc (AIM: PYC) is pleased to announce that the human Virtual Tumour (“VT”) project with Merck, a leading science and technology company, first announced in March 2015, has now been successfully completed and that it has today entered into a Master Services Agreement (“Agreement”) with Merck. Please click here to read in full...

  Dispatch of Documentation Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has published and posted to shareholders its Annual Report for the financial year ended 30th June 2017 and a circular in relation to its forthcoming Annual General Meeting As already announced on the 16th October 2017, the Company’s Annual General Meeting will be held at 10:00 a.m....

  Chairman's Statement Summary of Results in the year ended 30 June 2017 Total income (revenue and grant income) decreased 9% to £270,465 (2016: £297,120) The operating loss before exceptional costs increased 20% to £489,190 (2016: £408,614) The loss for the year attributable to equity shareholders increased 6% to £400,526 (2016: £378,697) On 30 June 2017, the surplus of shareholders’ funds was £328,254 (2016: £204,153) This year, Physiomics...